Cardiol Therapeutics Inc.

CRDLNASDAQHealthcare● Active

$1.08

$-0.03(-2.70%)

Market Cap$120821760

P/E Ratio—

52W High$1.71

52W Low$0.88

Avg Volume691K

Open$1.13

Beta0.80

Overview

Stock ranking:Drug Manufacturers - Specialty & Generic·Healthcare·View All Market Cap Rankings →

Cardiol Therapeutics Inc. (CRDL) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · CRDL · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-0.39Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)0.00Full revenue history

Dividend YieldNo DividendDividend history

Shares Outstanding87.0MShares outstanding history

Next EarningsAug 13, 2026Est.Earnings history

Explore Cardiol Therapeutics Inc. Data

Market Cap$120.8M

Analyst Forecast$8 · Buy

DividendsNo Dividend

Revenue—

EarningsEPS $-0.39+23.53%

PE Ratio—

Financial Snapshot

Full Financials

FY 2025Revenue$0.00

202320242025

FY 2025Net Income-$33.8M▲ +7.79% YoY

202320242025

FY 2025EPS$-0.39▲ +23.53% YoY

202320242025

TTM:Revenue: $0.00Net Income: -$36.4MEPS: $-0.39View income statement →

Analyst Ratings & Price Target

Full Forecast

Buy2 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

12-Month Price Target

$8.00Low

$1.08Current

$8.00Avg Target640.74% upside

$8.00High

Total: 2 · Buy rate: 100.0%

The CRDL analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month price target is $8.00, representing +640.74% upside from the current price of $1.08.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

CRDL

Cardiol Therapeutics Inc.

$1.08-2.70%$120.8M #2

ASRT

Assertio Holdings, Inc.

$23.43+0.02%$151.4M #3

CNTB

Connect Biopharma Holdings Limited

$2.20+2.95%$138.5M #4

HYPR

Hyperfine, Inc.

$1.41+2.12%$118.7M #5

IFRX

InflaRx N.V.

$1.71+0.29%$123.5M #6

IMA

ImageneBio Inc

$5.63-1.95%$63.5M

Stock Performance

Full History

1D-2.70%

1W-2.70%

1M-18.18%

3M+10.27%

YTD+13.23%

1Y-25.00%

5Y-59.54%

About Cardiol Therapeutics Inc.

CEODavid G. Elsley

IPO DateJan 15, 2019

Employees18

CountryCA

Websitecardiolrx.com

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading cand…

Drug Manufacturers - Specialty & Generic HealthcareNASDAQCA

About Stock Overview & Key Data

Cardiol Therapeutics Inc. (CRDL) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Jan 15, 2019. As of the latest trading session, CRDL stock price is $1.08, with a market capitalization of $120.8M. The stock has returned -25.00% over the past 12 months and +13.23% year-to-date.

According to 2 Wall Street analysts, the consensus rating for Cardiol Therapeutics Inc. stock is Buy, with an average 12-month price target of $8.00. In fiscal year 2025, Cardiol Therapeutics Inc. reported revenue of — and net income of -$33.8M. For detailed data — including Cardiol Therapeutics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Cardiol Therapeutics Inc. (CRDL) stock price is $1.08. The stock is traded on NASDAQ under the ticker symbol CRDL. The 52-week range is $0.88 – $1.71.

CRDL stock priceCRDL quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice